{"id":15376,"date":"2023-08-07T00:52:00","date_gmt":"2023-08-06T16:52:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15376"},"modified":"2024-11-28T01:00:00","modified_gmt":"2024-11-27T17:00:00","slug":"abvc-biopharma-grants-xinnovation-therapeutics-exclusive-rights-to-cns-drug-pipeline-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15376","title":{"rendered":"ABVC Biopharma Grants Xinnovation Therapeutics Exclusive Rights to CNS Drug Pipeline in China"},"content":{"rendered":"\n

US-based ABVC Biopharma Inc. has entered into a legally binding term sheet with China-based Xinnovation Therapeutics Co., Ltd., handing over exclusive rights to two of its central nervous system (CNS) disease drugs in the Chinese market. Under the agreement, Xinnovation will receive exclusive development, manufacturing, marketing, and distribution rights for ABV-1504, intended for major depressive disorder (MDD), and ABV-1505, for attention-deficit\/hyperactivity disorder (ADHD) in mainland China.<\/p>\n\n\n\n

Financial Terms and Potential Milestones<\/strong>
The deal is structured to provide ABVC with an aggregate income of USD 20 million if all milestones are achieved. A finalized agreement, including full terms and conditions, is yet to be signed by both firms. Additionally, ABVC stands to receive royalty payments ranging from 5% to 12% on any future net sales of the products in China.<\/p>\n\n\n\n

Botanical Drugs and Traditional Chinese Medicine<\/strong>
ABV-1504 and ABV-1505 are botanical drugs derived from the extract of the Polygala tenuifolia (Yuanzhi) root, which is commonly used in traditional Chinese medicine (TCM). Xinnovation will take on the responsibility of growing the root and conducting manufacturing processes in China, leveraging its local expertise and resources.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based ABVC Biopharma Inc. has entered into a legally binding term sheet with China-based Xinnovation…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2425,2426],"class_list":["post-15376","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-abvc-biopharma","tag-xinnovation-therapeutics"],"yoast_head":"\nABVC Biopharma Grants Xinnovation Therapeutics Exclusive Rights to CNS Drug Pipeline in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based ABVC Biopharma Inc. has entered into a legally binding term sheet with China-based Xinnovation Therapeutics Co., Ltd., handing over exclusive rights to two of its central nervous system (CNS) disease drugs in the Chinese market. Under the agreement, Xinnovation will receive exclusive development, manufacturing, marketing, and distribution rights for ABV-1504, intended for major depressive disorder (MDD), and ABV-1505, for attention-deficit\/hyperactivity disorder (ADHD) in mainland China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15376\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ABVC Biopharma Grants Xinnovation Therapeutics Exclusive Rights to CNS Drug Pipeline in China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15376\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-06T16:52:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-27T17:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15376#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15376\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"ABVC Biopharma Grants Xinnovation Therapeutics Exclusive Rights to CNS Drug Pipeline in China\",\"datePublished\":\"2023-08-06T16:52:00+00:00\",\"dateModified\":\"2024-11-27T17:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15376\"},\"wordCount\":197,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ABVC Biopharma\",\"Xinnovation Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15376#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15376\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15376\",\"name\":\"ABVC Biopharma Grants Xinnovation Therapeutics Exclusive Rights to CNS Drug Pipeline in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-06T16:52:00+00:00\",\"dateModified\":\"2024-11-27T17:00:00+00:00\",\"description\":\"US-based ABVC Biopharma Inc. has entered into a legally binding term sheet with China-based Xinnovation Therapeutics Co., Ltd., handing over exclusive rights to two of its central nervous system (CNS) disease drugs in the Chinese market. Under the agreement, Xinnovation will receive exclusive development, manufacturing, marketing, and distribution rights for ABV-1504, intended for major depressive disorder (MDD), and ABV-1505, for attention-deficit\\\/hyperactivity disorder (ADHD) in mainland China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15376#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15376\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15376#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ABVC Biopharma Grants Xinnovation Therapeutics Exclusive Rights to CNS Drug Pipeline in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ABVC Biopharma Grants Xinnovation Therapeutics Exclusive Rights to CNS Drug Pipeline in China - Insight, China's Pharmaceutical Industry","description":"US-based ABVC Biopharma Inc. has entered into a legally binding term sheet with China-based Xinnovation Therapeutics Co., Ltd., handing over exclusive rights to two of its central nervous system (CNS) disease drugs in the Chinese market. Under the agreement, Xinnovation will receive exclusive development, manufacturing, marketing, and distribution rights for ABV-1504, intended for major depressive disorder (MDD), and ABV-1505, for attention-deficit\/hyperactivity disorder (ADHD) in mainland China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15376","og_locale":"en_US","og_type":"article","og_title":"ABVC Biopharma Grants Xinnovation Therapeutics Exclusive Rights to CNS Drug Pipeline in China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15376","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-06T16:52:00+00:00","article_modified_time":"2024-11-27T17:00:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15376#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15376"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"ABVC Biopharma Grants Xinnovation Therapeutics Exclusive Rights to CNS Drug Pipeline in China","datePublished":"2023-08-06T16:52:00+00:00","dateModified":"2024-11-27T17:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15376"},"wordCount":197,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ABVC Biopharma","Xinnovation Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15376#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15376","url":"https:\/\/flcube.com\/?p=15376","name":"ABVC Biopharma Grants Xinnovation Therapeutics Exclusive Rights to CNS Drug Pipeline in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-06T16:52:00+00:00","dateModified":"2024-11-27T17:00:00+00:00","description":"US-based ABVC Biopharma Inc. has entered into a legally binding term sheet with China-based Xinnovation Therapeutics Co., Ltd., handing over exclusive rights to two of its central nervous system (CNS) disease drugs in the Chinese market. Under the agreement, Xinnovation will receive exclusive development, manufacturing, marketing, and distribution rights for ABV-1504, intended for major depressive disorder (MDD), and ABV-1505, for attention-deficit\/hyperactivity disorder (ADHD) in mainland China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15376#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15376"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15376#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"ABVC Biopharma Grants Xinnovation Therapeutics Exclusive Rights to CNS Drug Pipeline in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15376","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15376"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15376\/revisions"}],"predecessor-version":[{"id":15379,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15376\/revisions\/15379"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15376"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15376"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15376"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}